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Abstract 
By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial 
hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms 
(hypervolemia by the reduction of Na excretion and high rennin secretion) and the adaptation of the therapeutic approach to every 
patient. An individualized dialysis prescription is imposed, taking into account the residual renal function and an anti-hypertension 
treatment, in which the role of the conversion enzyme inhibitors (ACE inhibitor) is intensely debated.  
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In the majority of cases, arterial hypertension (HT) 
becomes therapeutically controllable with the 
implementation of renal substitution treatment, the rest of 
them being candidates for double nephrectomy. The link 
between the debut of the arterial hypertension and chronic 
hypertensive nephropathies has been noticed since 1836 
along with the research made by Richard Bright. These 
demonstrated the appearance of a rise in pressure values 
simultaneously with the evolution of the renal illness. 
Severe HT, essential HT or other non-renal causes can 
functionally affect the otherwise healthy kidneys, by 
inducing nephroangiosclerosis [1, 2]. HT represents an 
important factor of morbidity and mortality in dialysis 
patients, especially through the acceleration of the 
arteriosclerosis’ evolution and the evolution with 
complications, especially those of a cardiovascular cause: 
cardiac insufficiency, strokes, dissecting aneurysm.  
 
HT Causes: 
 
1. Chronic  glomerulonephritis   
2.  Systemic lupus erythematosus   
3.  Systemic atherosclerosis with nephroangiosclerosis 
4. Polyarteritis  nodossa 
5. Diabetic  nephropathy 
6. Polycystosis 
7. Amyloidosis 
In the majority of cases, dialysis patients develop 
terminal conditions of cardiovascular origin, associated 
with a history of arterial hypertension and advanced 
sclerosis. Recent studies have shown that there is no 
direct causality between mean arterial pressure and the 
survival rate; the left ventricular hypertrophy (LVH) 
incidence is increased in dialysis patients, and has a 
significant prognostic value - an important parameter for 
the monitoring, evaluation and evolution of the disease.  
Even if the pathogenesis of the LVH is of high 
variety (aortic pressure wave, hormonal imbalance rennin 
and PTH, renal anemia), it has been shown that this can 
be limited by administering the correct treatment - the 
association of dialysis with personal drug therapy, that 
keeps the arterial pressure values within acceptable limits 
(3). It is also of maximum importance that the BP value 
determination is made, in order to define the BP profile of 
the dialysis patient. The best time for this evaluation has 
proven to be a few hours post dialysis, considering the 
fact that, during the dialysis session, variations generated 
by the hemodynamic function requirements have been 
noted, with the volemic status taken into consideration in 
the pre-dialysis treatment. 
Nighttime measurements have shown significant 
decreases of values because of an autonomically 
acquired deficiency with a late debut of the chronic renal 
insufficiency. 
There have been documented cases in dialysis, in 
 
© 2010, Carol Davila University Foundation Journal of Medicine and Life Vol. 3, No.1, January-March 2010 
which, although before the onset of the substitute 
treatment, the subjects did not present with HT, they 
developed high values afterwards. These come secondary 
to their failure to meet their imposed dietary routine, even 
from technical mistakes during the dialysis procedure like 
hyperosmolarity of the dialysis patient, inadequate trans-
membrane pressure, or intravenous fluids during the 
dialysis. 
Several groups concerning the dialysis patients 
have been described based on the pathogenesis of the 
condition that can cross-link in some situations [1]: 
 
1.  Hydro-saline imbalance HT 
 
Hypervolemia HT seems to be the most frequent 
cause of hypertension affecting these patients, and this 
happened due to the complete failure of renal functions; 
these debuts as a consequence of reestablishing the 
electrolyte balance, with the secondary expansion of the 
extracellular liquid volume and the rise of non-
exchangeable Na. 
 
Consequences of the excess of Na 
The rise in the extra cellular liquid volume 
The rise in vascular reactivity on the action of pressure 
hormones 
The rise in peripheral vascular system resistance 
The rise in oabain-like substance secretion that limit the 
activity of the Na–K ATPasi   
The rise in adrenergic activity 
Structural changes of the vascular walls 
 
Therefore, along with the rise in water and Na 
intake, we observe a rise of the total plasma volume, 
cardiac output and peripheral vascular resistance, due to 
the local auto-regulation. These patients have shown low 
levels of rennin and angiotensin II (ATII) values, compared 
with their volemic status. 
The optimum treatment for these forms is 
established as: 
 
1.  Na intake restriction and the close 
supervision of liquid intake, correlated with 
the residual dieresis and non-detectable 
losses – an average of 10ml/kg/day. 
2.  Lowering plasma Na concentration to 133-
135 mEq/L 
3.  Daily or three times a week dialysis until 
patient reaches ideal weight  
 
The attention in establishing the patient’s ideal 
weight and the adaptation of dialysis recommendations 
may assure the correction of pressure values and their 
stability. 
 
2.  Rennin dependent HT (normal volemia HT) 
 
This type of HT is an altogether different entity, 
which imposes differential diagnostic issues with the 
hypervolemia type, making it hard to be diagnosed 
independently because of the etiological cross-linkage: 
plasma rennin, ATII, aldosterone, and peripheral 
resistance are high, with a normal or low serum Na 
concentration and plasma volume. 
Clinically, this form of HT is a malignant 
development, hard to control, but often with a spectacular 
result after the administration of ACE inhibitors. For 
patients on dialysis with therapy-resistant HT, we could 
incriminate a hyperactivity of plasma rennin even after 
ultra-filtration and ideal-weight adapted dialysis. The 
administration of ACE inhibitor therapy for these patients 
has lead to a net improvement of their HT status [5], 
nevertheless, there have been cases which have required 
the removal of the rennin source and the reestablishing of 
pressure balance by-nephrectomy. 
Physiopathology studies have recorded paradoxical 
vascular reactions to any exceeding volemic homeostasis 
values. Furthermore, the therapeutic loss of salt by 
dialysis may be the source of ulterior activity of renal 
vasopressor mechanisms and the generating of HT 
phenomena hard to control. 
The balance between cardiac output and peripheral 
vascular resistance determines the arterial pressure. Most 
studies indicate that the cardiac output is normal or above, 
while extracellular liquid volume is relatively high in 
patients with chronic renal insufficiency (CRI); systemic 
vascular resistance is abnormally high relatively to cardiac 
output, this revealing a switch in the vascular control 
mechanism towards vasoconstriction. Therefore, patients 
with CRI show an increased adrenergic tonus and some 
highly stimulated rennin-angiotensin, endothelin and 
vasoactive prostaglandins systems. Another aspect 
observed in some situations is that of diminished nitric 
oxide (NO) production which reduces the vasodilatation 
potency. 
The link between renal perfusion pressure and salt 
excretion, which defines pressure natriuresis, has been an 
element of interest for many studies. In essential HT, a 
higher renal perfusion pressure is imposed in order to 
stabilize the sodium balance, but not the same thing 
happens in patients with renal parenchyma disease, 
where natriuresis is perturbed by the loss of renal tissue 
mass. The same effects are also noticed when dealing 
with endocrine dysfunctions which have an effect on salt 
excretion (aldosterone-stimulated kidneys), or in the case 
of diminished renal blood flow and stenosis of the renal 
artery (Goldblatt kidneys) [9]. 
The necessity to control arterial blood pressure in 
patients with terminal renal insufficiency and dialysis 
patients has imposed the detailed study of the sodium 
plasma levels in concordance with ultra-filtration. 
Gathered data include body weight, plasma rennin activity 
and arterial blood pressure (before and after the 
administration of ACE inhibitors), on a period of 11 days of 
treatment. Rigorous ultra-filtration has been performed on 
these patients set on a low Na diet, in order to obtain a 
negative Na balance.  
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We have observed the increase in plasma rennin 
concentration, concomitant with sodium extraction, and 
the values for arterial pressure depends on rennin-ATII 
system, as we can see after the administration of the ACE 
inhibitor (captoprilum). In conclusion, the reduction of 
extracellular liquid volume and sodium plasma levels is 
essential for the establishing of an efficient control of 
arterial BP values in patients with CRI. 
The relevance of the interaction between sodium 
and rennin-angiotensin balance in malignant HT is 
revealed by a study made on a group of subjects with 
renal dysfunction and accelerated HT. Lowering the BP 
values after the administration of ACE inhibitors is abruptly 
altered after the infusion of saline solution, with the 
establishing of a positive Na balance and the reduced 
plasma rennin concentration. Administering a strong 
diuretic induces net sodium excretion, restimulates the 
rennin synthesis and reestablishes the sensibility to ACE 
inhibitor therapy. These observations establish the 
reciprocal relationship between the Na status and the level 
of circulating rennin. 
The latest studies made on dialysis patients who 
have over 8 years of treatment, have shown that there is 
no correlation between plasma rennin levels and diastolic 
BP. In the same time, these studies indicate that severe 
HT in dialysis patients is an account not only of the nigh 
plasma rennin activity and ATII generation and extraction, 
but also of the overlapping excess of salt and water [6, 8]. 
Therefore, the rennin mechanism interferes with the 
hydro-electrolytic balance, summing their effects and 
generating a complicated HT syndrome. These patients 
associate secondary distance phenomena like vision 
impairment, retinal hemorrhage, state of conscience 
dysfunctions or angina and may, at the same time, 
present anorexia, nausea and intense thirst. 
Adapting the therapy by associating an adequate 
ultra-filtration and the administration of an anti-
hypertensive medication based on ACE inhibitors, with a 
prolonged half time, associated or not with other 
categories of anti-hypertensive drugs, is the key in 
managing this type of HT. 
ACE inhibitors act directly by interfering with the 
rennin-angiotensin-aldosterone system, which makes their  
 
use become attractive in the therapy of dialysis patients.  
They are a class of anti-hypertensive drugs generally well 
tolerated, with low side effects like the lethargy-
somnolence syndrome or other effects shown by anti-
adrenergic and beta-blocker drugs.  
In dialysis patients, the level of prekalicreine is low 
and that if ACE is high; high plasma rennin activity may be 
correlated with the increase of aortic pressure. ATII 
accelerates LVH and that is why the use of ACE inhibitors 
may stop and even make LVH regress. ACE inhibitors are 
useful in congestive cardiac insufficiency by reducing the 
thirst sensation, which is characteristic for high plasma 
rennin levels, this limiting the weight-gain between dialysis 
procedures. 
The utilization of captoprilum, has been 
associated with side-effects like: 
1.  Skin rash 
2.  Cough 
3.  Leucopenia or neutropenia 
4.  Acceleration of anemia 
This last effect has become notable after the 
association of ACE inhibitor therapy with 
the diminishing of plasma erythropoietin (EPO) or with an 
increased degree of hemolysis. The explanation for this 
phenomenon may lie in the direct interference of ATII, with 
the transcription signal for EPO at a cellular level.  
ACE inhibitors reduce arterial blood pressure by 
lowering peripheral vascular resistance because of the 
blocked formation of ATII, but there are also other 
collateral mechanisms. That is why most cases require the 
administration of more than one class of anti-hypertensive 
drugs [6]. 
In conclusion, the management of HT in dialysis 
patients is linked especially to the disease that causes 
chronic nephropathy, the substrate of the terminal renal 
insufficiency, the presence of co-morbidities, the evolution 
of HT before the start of renal substitution therapy and 
during dialysis therapy.   
The optimal attitude is that of continuous evaluation 
and monitoring of the patient, with the adaptation of 
therapy by accurately combining the recommendation for 
dialysis and anti-hypertensive medication, all this in order 
to reach the aimed arterial blood pressure values. 
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